RU2283108C2 - ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ - Google Patents
ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ Download PDFInfo
- Publication number
- RU2283108C2 RU2283108C2 RU2003135482/15A RU2003135482A RU2283108C2 RU 2283108 C2 RU2283108 C2 RU 2283108C2 RU 2003135482/15 A RU2003135482/15 A RU 2003135482/15A RU 2003135482 A RU2003135482 A RU 2003135482A RU 2283108 C2 RU2283108 C2 RU 2283108C2
- Authority
- RU
- Russia
- Prior art keywords
- formula
- corresponds
- compound
- group
- pyrido
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 10
- 239000002831 pharmacologic agent Substances 0.000 title claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 title abstract description 7
- 150000002475 indoles Chemical class 0.000 title description 3
- 230000002398 geroprotective effect Effects 0.000 claims abstract description 11
- 206010063493 Premature ageing Diseases 0.000 claims abstract description 9
- 208000032038 Premature aging Diseases 0.000 claims abstract description 9
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical class C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 53
- 208000002177 Cataract Diseases 0.000 claims description 14
- 229940125384 geroprotector Drugs 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 23
- 239000000126 substance Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 40
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 239000011575 calcium Substances 0.000 description 14
- 230000032683 aging Effects 0.000 description 12
- 230000004393 visual impairment Effects 0.000 description 9
- 230000007170 pathology Effects 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 206010047571 Visual impairment Diseases 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000029257 vision disease Diseases 0.000 description 5
- XWLFAMANDIWUKH-UHFFFAOYSA-N 2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole-2,5-diium;dichloride Chemical compound Cl.Cl.N1C2=CC=C(C)C=C2C2C1CCN(C)C2 XWLFAMANDIWUKH-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 description 4
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 208000018769 loss of vision Diseases 0.000 description 4
- 231100000864 loss of vision Toxicity 0.000 description 4
- 210000003568 synaptosome Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- -1 2,8-dimethyl-5-benzyl-2,3,4,5-tetrahydro-1H-pyrido [4,3-b] indole hydrochloride Chemical compound 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 3
- 229960003987 melatonin Drugs 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CYJQCYXRNNCURD-DGCLKSJQSA-N (4ar,9bs)-2,8-dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2[C@@H]2[C@H]1CCN(C)C2 CYJQCYXRNNCURD-DGCLKSJQSA-N 0.000 description 2
- JIHMATXQZDSUOR-UHFFFAOYSA-N 2,3,4,4a,5,5a-hexahydro-1h-pyrido[4,3-b]indole Chemical class N1C2C=CC=CC2=C2C1CCNC2 JIHMATXQZDSUOR-UHFFFAOYSA-N 0.000 description 2
- TWZCZLLZJDKWFN-UHFFFAOYSA-N 2-benzyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound C1CC=2NC3=CC=CC=C3C=2CN1CC1=CC=CC=C1 TWZCZLLZJDKWFN-UHFFFAOYSA-N 0.000 description 2
- MYUAGMGKBGUWEN-UHFFFAOYSA-N 2-ethyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCN(CC)C2 MYUAGMGKBGUWEN-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 2
- 239000004258 Ethoxyquin Substances 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 2
- 235000019285 ethoxyquin Nutrition 0.000 description 2
- 229940093500 ethoxyquin Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000008525 senile cataract Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BPPMRCNUQCVVFJ-UHFFFAOYSA-N 2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical class N1C2=CC=CC=C2C2C1CCNC2 BPPMRCNUQCVVFJ-UHFFFAOYSA-N 0.000 description 1
- 150000008591 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles Chemical class 0.000 description 1
- MUZFLDUALLSEBH-UHFFFAOYSA-N 2,8-dimethyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2C2=C1CCN(C)C2 MUZFLDUALLSEBH-UHFFFAOYSA-N 0.000 description 1
- GTWLIQOLGOZTLF-UHFFFAOYSA-N 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole;dihydrochloride Chemical compound Cl.Cl.C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 GTWLIQOLGOZTLF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FYHWPFXPFFPQRT-UHFFFAOYSA-N 2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCN(C)C2 FYHWPFXPFFPQRT-UHFFFAOYSA-N 0.000 description 1
- UPLUVROGBHSYKI-UHFFFAOYSA-N 2-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CCC1=CC=C(C)N=C1 UPLUVROGBHSYKI-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- NGNVOGPUTBVHTL-UHFFFAOYSA-N 5-benzyl-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1=CC=CC=C1 NGNVOGPUTBVHTL-UHFFFAOYSA-N 0.000 description 1
- HFILMDDJKHXWEL-UHFFFAOYSA-N 8-bromo-2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(Br)C=C2C2=C1CCN(C)C2 HFILMDDJKHXWEL-UHFFFAOYSA-N 0.000 description 1
- BREYYQBMCNPIAW-UHFFFAOYSA-N 8-bromo-2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole;hydrochloride Chemical compound Cl.N1C2=CC=C(Br)C=C2C2=C1CCN(C)C2 BREYYQBMCNPIAW-UHFFFAOYSA-N 0.000 description 1
- WCTGYFWVYBPRGF-UHFFFAOYSA-N 8-chloro-2-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CCC1=CC=C(C)N=C1 WCTGYFWVYBPRGF-UHFFFAOYSA-N 0.000 description 1
- XGGILFZLGXIRFW-UHFFFAOYSA-N 8-chloro-2-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole;dihydrochloride Chemical compound Cl.Cl.C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CCC1=CC=C(C)N=C1 XGGILFZLGXIRFW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 0 Cc(cc1)cc2c1[n](C)c1c2CN(*)CC1 Chemical compound Cc(cc1)cc2c1[n](C)c1c2CN(*)CC1 0.000 description 1
- HAULBYQNKWZDLX-UHFFFAOYSA-N Cl.Cl.C1CN=NC1.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 Chemical compound Cl.Cl.C1CN=NC1.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 HAULBYQNKWZDLX-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- OVGORFFCBUIFIA-UHFFFAOYSA-N Fenipentol Chemical compound CCCCC(O)C1=CC=CC=C1 OVGORFFCBUIFIA-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020915 Hypervitaminosis Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CJUOSBUQOWKEKJ-UHFFFAOYSA-N Mebhydrolin napadisilate Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 CJUOSBUQOWKEKJ-UHFFFAOYSA-N 0.000 description 1
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002539 anti-aggressive effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229950000904 dorastine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- FQQIIPAOSKSOJM-UHFFFAOYSA-N mebhydrolin Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 FQQIIPAOSKSOJM-UHFFFAOYSA-N 0.000 description 1
- 229960004934 mebhydrolin Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2003135482/15A RU2283108C2 (ru) | 2003-12-08 | 2003-12-08 | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| JP2006543944A JP2007513201A (ja) | 2003-12-08 | 2004-12-08 | 老化を遅らせるための方法および組成物 |
| PCT/US2004/041081 WO2005055951A2 (en) | 2003-12-08 | 2004-12-08 | Methods and compositions for slowing aging |
| CA002548487A CA2548487A1 (en) | 2003-12-08 | 2004-12-08 | Methods and compositions for slowing aging |
| US10/582,312 US20080234310A1 (en) | 2003-12-08 | 2004-12-08 | Methods and Compositions for Slowing Aging |
| AU2004296861A AU2004296861A1 (en) | 2003-12-08 | 2004-12-08 | Methods and compositions for slowing aging |
| EP04813405A EP1692131A4 (en) | 2003-12-08 | 2004-12-08 | METHODS AND COMPOSITIONS FOR SLOWDING AGING |
| US11/644,698 US20070179174A1 (en) | 2003-12-08 | 2006-12-22 | Methods and compositions for slowing aging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2003135482/15A RU2283108C2 (ru) | 2003-12-08 | 2003-12-08 | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003135482A RU2003135482A (ru) | 2005-05-20 |
| RU2283108C2 true RU2283108C2 (ru) | 2006-09-10 |
Family
ID=34676076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003135482/15A RU2283108C2 (ru) | 2003-12-08 | 2003-12-08 | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080234310A1 (https=) |
| EP (1) | EP1692131A4 (https=) |
| JP (1) | JP2007513201A (https=) |
| AU (1) | AU2004296861A1 (https=) |
| CA (1) | CA2548487A1 (https=) |
| RU (1) | RU2283108C2 (https=) |
| WO (1) | WO2005055951A2 (https=) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008060190A3 (en) * | 2006-11-16 | 2008-07-24 | Alla Chem Llc | Ligands of 5-ht6 receptors, a pharmaceutical composition, method for the production and use thereof |
| RU2334514C1 (ru) * | 2006-12-01 | 2008-09-27 | Институт физиологически активных веществ Российской Академии наук | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| RU2340342C2 (ru) * | 2006-12-07 | 2008-12-10 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| WO2008123796A3 (ru) * | 2007-04-05 | 2008-12-31 | Alla Chem Llc | Замещенные 2,3,4,5-tetpaгидpo-1h-пиpидo[4,3-b]иhдoлы, способ их получения и применения |
| RU2351350C1 (ru) * | 2007-11-13 | 2009-04-10 | Закрытое акционерное общество Научно-производственное предприятие "Тринита" | Набор "предстар", его применение и способ предупреждения преждевременного старения организма |
| WO2009082268A3 (ru) * | 2007-12-21 | 2009-08-20 | Ivashchenko Andrey Alexandrovi | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ |
| WO2010024717A1 (ru) * | 2008-08-22 | 2010-03-04 | Алла Xem, Ллс | Лиганд с широким спектром фармакологической активности, фармацевтическая композиция, лекарственное средство и способ лечения |
| RU2836779C1 (ru) * | 2024-10-02 | 2025-03-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" | 4-(2-(ПИРИДИН-2-ИЛ)-9H-ПИРИДО[2,3-b]ИНДОЛ-8-ИЛ)АНИЛИН - КЛЕТОЧНЫЙ ФЛУОРЕСЦЕНТНЫЙ КРАСИТЕЛЬ |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2106864C1 (ru) | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
| US20070179174A1 (en) * | 2003-12-08 | 2007-08-02 | Bachurin Sergei O | Methods and compositions for slowing aging |
| US20070117834A1 (en) * | 2005-10-04 | 2007-05-24 | David Hung | Methods and compositions for treating Huntington's disease |
| RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| JP2010504338A (ja) * | 2006-09-20 | 2010-02-12 | メディベイション ニューロロジー， インコーポレイテッド | 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール |
| EP2066322A2 (en) * | 2006-09-20 | 2009-06-10 | Medivation Neurology, Inc. | Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine cognitive dysfunction syndrome |
| WO2008051599A2 (en) | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil |
| AU2008302751A1 (en) * | 2007-09-20 | 2009-03-26 | D2E, Llc | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2009120717A2 (en) | 2008-03-24 | 2009-10-01 | Medivation Technologies, Inc. | Pyrido [3, 4-b] indoles and methods of use |
| CL2009000725A1 (es) | 2008-03-24 | 2009-05-29 | Medivation Technologies Inc | Compuestos derivados de heterociclos con uniones puente sustituidos, moduladores de receptores adrenergicos, de serotonina, de dopamina y de histaminas; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento del trastorno cognitivo y trastorno psicotico. |
| AU2009308708B2 (en) | 2008-10-31 | 2015-11-19 | Medivation Technologies, Inc. | Azepino [4, 5-b] indoles and methods of use |
| TWI477503B (zh) * | 2008-10-31 | 2015-03-21 | Medivation Technologies Inc | 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚 |
| CN102300578A (zh) * | 2008-12-01 | 2011-12-28 | 延寿有限责任公司 | 用于改变健康、安康和寿命的方法和组合物 |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
| US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| CA2748813C (en) | 2009-01-09 | 2018-07-10 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| BRPI1008020A2 (pt) | 2009-02-11 | 2016-03-15 | Sunovion Pharmaceuticals Inc | antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos |
| EP2236160A3 (en) | 2009-03-31 | 2011-12-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release dimebolin formulations |
| EP2236159A3 (en) | 2009-03-31 | 2011-12-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release dimebolin compositions |
| TR200903014A1 (tr) | 2009-04-17 | 2010-11-22 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Oral yolla dağılan dimebolin bileşimleri. |
| CA2760541A1 (en) | 2009-04-29 | 2010-11-04 | Medivation Technologies, Inc. | Pyrido[4,3-b] indoles and methods of use |
| MX2012002898A (es) * | 2009-09-11 | 2012-04-02 | Sunovion Pharmaceuticals Inc | Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos. |
| WO2011038164A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
| US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| CA2775328A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| TR201001117A1 (tr) | 2010-02-15 | 2011-09-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Dimebolin ve memantin kombinasyonları |
| WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103433A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| CA2804161A1 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| WO2012112963A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| US8791132B2 (en) | 2011-02-18 | 2014-07-29 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| CA2882826A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
| EP3068388A4 (en) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Neuroprotective compounds and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3718657A (en) * | 1970-12-03 | 1973-02-27 | Abbott Lab | Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines |
| RU2106864C1 (ru) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3743740A (en) * | 1968-10-31 | 1973-07-03 | I Zhukova | 3,6-dimethyl - 1,2,3,4,4a,9a - hexahydro-ypsilon-carboline dihydrochloride for treating mental diseases |
| AR205452A1 (es) * | 1973-12-06 | 1976-05-07 | Endo Lab | Metodo para preparar nuevos trans-2, 3, 4, 4a, 5, 9b-hexahidro-5-fenil-1h-pirido(4,3-b) indoles |
| US4174453A (en) * | 1973-12-06 | 1979-11-13 | Endo Laboratories, Inc. | Trans-hexahydro-pyrido-indoles |
| US4636563A (en) * | 1985-09-16 | 1987-01-13 | American Home Products Corporation | Antipsychotic γ-carbolines |
| US4985256A (en) * | 1988-04-27 | 1991-01-15 | Bionix Corporation | Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory |
| US6017957A (en) * | 1989-08-08 | 2000-01-25 | The United States Of America As Represented By The Department Of Health And Human Services | Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents |
| US5319096A (en) * | 1992-04-03 | 1994-06-07 | Hoechst-Roussel Pharmaceuticals Inc. | (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use |
| US6362160B1 (en) * | 1993-06-30 | 2002-03-26 | The Johns Hopkins University School Of Medicine | Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases |
| US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| GB9418326D0 (en) * | 1994-09-12 | 1994-11-02 | Lilly Industries Ltd | Pharmaceutical compounds |
| US5958919A (en) * | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
| US6391871B1 (en) * | 1996-09-20 | 2002-05-21 | John W. Olney | Preventing neuronal degeneration in Alzheimer's disease |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| US6379882B1 (en) * | 1998-09-14 | 2002-04-30 | Elan Pharmaceuticals, Inc. | Method for selecting compounds for treating ischemia-related cellular damage |
| NZ519447A (en) * | 1999-12-16 | 2004-03-26 | Biogen Inc | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| US20070179174A1 (en) * | 2003-12-08 | 2007-08-02 | Bachurin Sergei O | Methods and compositions for slowing aging |
| US20070117834A1 (en) * | 2005-10-04 | 2007-05-24 | David Hung | Methods and compositions for treating Huntington's disease |
-
2003
- 2003-12-08 RU RU2003135482/15A patent/RU2283108C2/ru not_active IP Right Cessation
-
2004
- 2004-12-08 EP EP04813405A patent/EP1692131A4/en not_active Withdrawn
- 2004-12-08 WO PCT/US2004/041081 patent/WO2005055951A2/en not_active Ceased
- 2004-12-08 AU AU2004296861A patent/AU2004296861A1/en not_active Abandoned
- 2004-12-08 JP JP2006543944A patent/JP2007513201A/ja active Pending
- 2004-12-08 CA CA002548487A patent/CA2548487A1/en not_active Abandoned
- 2004-12-08 US US10/582,312 patent/US20080234310A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3718657A (en) * | 1970-12-03 | 1973-02-27 | Abbott Lab | Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines |
| RU2106864C1 (ru) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
Non-Patent Citations (1)
| Title |
|---|
| Машковский М.Д. Лекарственные средства. М.: Медицина, 1993, ч.1, с.375. * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008060190A3 (en) * | 2006-11-16 | 2008-07-24 | Alla Chem Llc | Ligands of 5-ht6 receptors, a pharmaceutical composition, method for the production and use thereof |
| RU2334514C1 (ru) * | 2006-12-01 | 2008-09-27 | Институт физиологически активных веществ Российской Академии наук | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| RU2340342C2 (ru) * | 2006-12-07 | 2008-12-10 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| WO2008123796A3 (ru) * | 2007-04-05 | 2008-12-31 | Alla Chem Llc | Замещенные 2,3,4,5-tetpaгидpo-1h-пиpидo[4,3-b]иhдoлы, способ их получения и применения |
| EA016234B1 (ru) * | 2007-04-05 | 2012-03-30 | Андрей Александрович ИВАЩЕНКО | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| US8541437B2 (en) | 2007-04-05 | 2013-09-24 | Alla Chem, Llc | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for the production and use thereof |
| RU2351350C1 (ru) * | 2007-11-13 | 2009-04-10 | Закрытое акционерное общество Научно-производственное предприятие "Тринита" | Набор "предстар", его применение и способ предупреждения преждевременного старения организма |
| WO2009082268A3 (ru) * | 2007-12-21 | 2009-08-20 | Ivashchenko Andrey Alexandrovi | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ |
| WO2010024717A1 (ru) * | 2008-08-22 | 2010-03-04 | Алла Xem, Ллс | Лиганд с широким спектром фармакологической активности, фармацевтическая композиция, лекарственное средство и способ лечения |
| EA018788B1 (ru) * | 2008-08-22 | 2013-10-30 | Андрей Александрович ИВАЩЕНКО | Лиганд с широким спектром фармакологической активности и его применение |
| RU2836779C1 (ru) * | 2024-10-02 | 2025-03-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" | 4-(2-(ПИРИДИН-2-ИЛ)-9H-ПИРИДО[2,3-b]ИНДОЛ-8-ИЛ)АНИЛИН - КЛЕТОЧНЫЙ ФЛУОРЕСЦЕНТНЫЙ КРАСИТЕЛЬ |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1692131A4 (en) | 2008-08-20 |
| RU2003135482A (ru) | 2005-05-20 |
| WO2005055951A3 (en) | 2005-12-08 |
| JP2007513201A (ja) | 2007-05-24 |
| EP1692131A2 (en) | 2006-08-23 |
| CA2548487A1 (en) | 2005-06-23 |
| US20080234310A1 (en) | 2008-09-25 |
| AU2004296861A1 (en) | 2005-06-23 |
| WO2005055951A2 (en) | 2005-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2283108C2 (ru) | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ | |
| RU2106864C1 (ru) | Средство для лечения болезни альцгеймера | |
| RU2338533C1 (ru) | СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ | |
| US20070179174A1 (en) | Methods and compositions for slowing aging | |
| US20070117835A1 (en) | Methods and compositions for treating Huntington's disease | |
| JP2022116191A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| TWI452039B (zh) | 抗神經變性疾病用劑 | |
| US10004744B2 (en) | Therapeutic approaches for treating Parkinson's disease | |
| KR20090087009A (ko) | 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법 | |
| SK14922002A3 (sk) | Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru | |
| CN101406470A (zh) | 吡啶杂环衍生物的用途及含其的药物组合物 | |
| RU2340342C2 (ru) | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ | |
| JP6803898B2 (ja) | オメガ−３脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ | |
| US20210128593A1 (en) | Synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction | |
| CA1169775A (fr) | Composition pharmaceutique notamment a action anti- ischemique | |
| JP2018508479A (ja) | 虚血性脳卒中を予防・治療するための薬物の調製におけるビフェノールの使用 | |
| JP2018503637A (ja) | ビフェニル誘導体及びその使用 | |
| US10709687B2 (en) | FLT3 receptor inhibitor at low dosage for the treatment of neuropathic pain | |
| ES2689042T3 (es) | Uso de 3-n-butil isoindolina cetona en la preparación de fármacos para prevenir y tratar el infarto cerebral | |
| CA3181134A1 (en) | Dihomo-gamma linolenic acid (dgla) is a novel senolytic | |
| US20250057805A1 (en) | Methods for addressing injection site reactions associated with the administration of bevemipretide | |
| MXPA06015196A (es) | Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide. | |
| JPH0587048B2 (https=) | ||
| JP2019519480A (ja) | パーキンソン病患者において転倒を低減するためのアセチルコリンエステラーゼ阻害剤およびイダロピルジンの使用 | |
| EP1897549A1 (en) | Radical scavenger and active oxygen eliminating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060111 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20060419 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151209 |